- Home
- ECF vs GNLX Comparison
ECF vs GNLX Comparison
Compare ECF & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECF
- GNLX
- Stock Information
- Founded
- ECF 1986
- GNLX 2001
- Country
- ECF United States
- GNLX United States
- Employees
- ECF N/A
- GNLX N/A
- Industry
- ECF Finance/Investors Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- ECF Finance
- GNLX Health Care
- Exchange
- ECF Nasdaq
- GNLX Nasdaq
- Market Cap
- ECF 136.5M
- GNLX 103.6M
- IPO Year
- ECF N/A
- GNLX 2023
- Fundamental
- Price
- ECF $9.58
- GNLX $2.27
- Analyst Decision
- ECF
- GNLX Strong Buy
- Analyst Count
- ECF 0
- GNLX 4
- Target Price
- ECF N/A
- GNLX $18.25
- AVG Volume (30 Days)
- ECF 57.7K
- GNLX 141.5K
- Earning Date
- ECF 01-01-0001
- GNLX 11-14-2024
- Dividend Yield
- ECF 6.42%
- GNLX N/A
- EPS Growth
- ECF N/A
- GNLX N/A
- EPS
- ECF 0.46
- GNLX N/A
- Revenue
- ECF N/A
- GNLX $8,000.00
- Revenue This Year
- ECF N/A
- GNLX N/A
- Revenue Next Year
- ECF N/A
- GNLX N/A
- P/E Ratio
- ECF $17.61
- GNLX N/A
- Revenue Growth
- ECF N/A
- GNLX N/A
- 52 Week Low
- ECF $7.02
- GNLX $1.60
- 52 Week High
- ECF $8.91
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- ECF 42.15
- GNLX 38.68
- Support Level
- ECF $9.48
- GNLX $2.13
- Resistance Level
- ECF $9.93
- GNLX $2.80
- Average True Range (ATR)
- ECF 0.10
- GNLX 0.20
- MACD
- ECF -0.06
- GNLX -0.04
- Stochastic Oscillator
- ECF 18.18
- GNLX 14.21
About ECF Ellsworth Growth and Income Fund Ltd.
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.